
Across the country, adult children increasingly manage the health decisions that shape their parents’ futures. They schedule appointments, organize medications, and gently navigate conversations about safety, independence, and memory. Neurogen Biomarking was designed for this reality. By pairing research-grade biomarkers with neurologist interpretation and an at-home experience, Neurogen gives families earlier answers on Alzheimer’s risk and a clear path forward that respects both science and dignity.
Caregiving often turns on small but unsettling moments. A bill goes unpaid, a story is retold, a name sits just out of reach. Families want to help without creating fear. They seek clarity without long waits or confusing referrals. Neurogen meets that moment with a premium, clinician-led service that is private, streamlined, and grounded in validated methods. Loved ones can initiate testing, complete a simple at-home blood collection and a digital cognitive assessment, and then meet by telehealth with a board-certified neurologist who explains what the results mean and what to do next.
Before the formal launch, Neurogen’s waitlist surpassed one thousand people. In beta operations, more than five hundred individuals completed the pathway, with 98 percent reporting satisfaction. A significant share of purchases came from adult children buying on behalf of a parent. The signal is clear. Families want earlier insight, qualified guidance, and direction that converts scattered data into practical decisions.
A small blood sample measures phosphorylated tau 217, a biomarker associated with early Alzheimer’s pathology. A modern, cognitive assessment captures attention, memory, and processing indicators. A board-certified neurologist integrates these inputs with clinical context, such as kidney function, cerebrovascular history, medications, sleep, and cardiovascular risks, to build a personalized plan with clear next steps. The result is not a number. The result is a plan families can implement together.
The objective is guidance that families can act on today and track over time. Neurogen was founded by practicing clinicians and clinical trial leaders who insist on responsible screening standards. Results are never delivered without interpretation, and the Scientific Advisory Committee includes experts from leading academic centers to ensure alignment with current evidence. Privacy, informed consent, and respectful communication are table stakes for every interaction.
Families choose Neurogen for access without delay, clinical confidence through specialist interpretation, dignity for parents through at-home logistics, and actionable next steps that are clear and achievable. The service converts concern into a pathway that families and clinicians can follow together.
Jordan French is the Founder and Executive Editor of Grit Daily Group , encompassing Financial Tech Times, Smartech Daily, Transit Tomorrow, BlockTelegraph, Meditech Today, High Net Worth magazine, Luxury Miami magazine, CEO Official magazine, Luxury LA magazine, and flagship outlet, Grit Daily. The champion of live journalism, Grit Daily's team hails from ABC, CBS, CNN, Entrepreneur, Fast Company, Forbes, Fox, PopSugar, SF Chronicle, VentureBeat, Verge, Vice, and Vox. An award-winning journalist, he was on the editorial staff at TheStreet.com and a Fast 50 and Inc. 500-ranked entrepreneur with one sale. Formerly an engineer and intellectual-property attorney, his third company, BeeHex, rose to fame for its "3D printed pizza for astronauts" and is now a military contractor. A prolific investor, he's invested in 50+ early stage startups with 10+ exits through 2023.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.